What the Study Found (In Plain English)
Published in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Prehospital neuroprotectant therapy in combination with thrombolysis is a potential treatment strategy in acute ischemic stroke allowing for earlier therapy start and bridging period until in-hospital therapies. Key clinical takeaway: Prehospital magnesium followed by alteplase was feasible and safe but did not demonstrate a significant overall clinical benefit.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2026-09-15; Phase III Randomized Trial; Rigor 88/100): Prehospital magnesium followed by alteplase was feasible and safe but did not demonstrate a significant overall clinical benefit.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.